The tocilizumab groups had fewer serious adverse events (14–15%) than the placebo groups (22–25%). However, one patient in the group that received tocilizumab bi-weekly developed anterior ischemic optic neuropathy. The authors call for longer follow-up to determine the durability of remission and the long-term safety of tocilizumab.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.